Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Gynaecological cancers

742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer

Date

22 Oct 2023

Session

Mini oral session - Gynaecological cancers

Topics

Clinical Research;  Tumour Immunology;  Translational Research;  Immunotherapy

Tumour Site

Endometrial Cancer

Presenters

Marco de Bruyn

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

M. de Bruyn1, A.L. Eerkens1, K. Brummel2, A. Vledder1, S.T. Paijens3, M. Requesens1, D. Loiero4, N. van Rooij1, A. Plat1, P. Klok1, F. Haan1, D.N. Church5, R. Wardenaar6, F. Foijer6, V.H. Koelzer4, T. Bosse7, J. Bart8, M. Jalving9, A.K.L. Reyners10, H.W. Nijman1

Author affiliations

  • 1 Gynaecology & Obstetrics, UMCG - University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 2 Obstetrics And Gynecology, UMCG - University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 3 Radiotherapy, Erasmus MC, 3000 CA - Rotterdam/NL
  • 4 Institut Für Pathologie Und Molekularpathologie, USZ - Universitätsspital Zürich, 8091 - Zurich/CH
  • 5 Oncology Department, University of Oxford, OX3 7DQ - Oxford/GB
  • 6 European Research Institute For The Biology Of Ageing (eriba), UMCG - University Medical Center Groningen, 9713 AV - Groningen/NL
  • 7 Pathology, Leiden University Medical Center, 2300 RC - Leiden/NL
  • 8 Pathology, UMCG - University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 9 Medical Oncology Department, UMCG - University Medical Center Groningen, 9700 RB - Groningen/NL
  • 10 Medical Oncology, UMCG - University Medical Center Groningen, 9700 RB - Groningen/NL

Resources

This content is available to ESMO members and event participants.

Abstract 742MO

Background

Recent studies suggest neoadjuvant immune checkpoint blockade (ICB) may be more efficacious than adjuvant treatment in mismatch repair deficient (MMRd) cancers. However, this has not been explored for endometrial cancer (EC). Here, we report results from a phase I feasibility study of neoadjuvant pembrolizumab in 10 MMRd EC patients.

Methods

MMRd EC patients of any stage or grade at intent-to-treat with primary surgery (at least a hysterectomy) were eligible for participation, and 10/10 patients have been recruited. Patients were treated with 2 three-weekly cycles of pembrolizumab monotherapy (200mg iv) prior to standard-of-care resection and adjuvant treatment if indicated. Radiologic and pathologic response rates, treatment-related adverse events (trAEs) and immune correlates of treatment were assessed.

Results

Patients had stage I-II (n=4) or stage III (n=6) disease at diagnosis, remained on-protocol and underwent definitive surgery. In patients with measurable disease on MRI (n=8), a partial radiologic response was observed in 3/8 patients. A pathological response (<90% viable cancer cells) was observed in 5/10 patients, with 2 major pathologic responses (<10% viable cancer cells). To date, no recurrences have been observed, with a median and longest disease-free survival of 17 and 26 months, respectively. Subclonal MMRp was observed in 2 patients after neoadjuvant treatment. 9/10 patients experienced grade 1/2 trAEs. A treatment-induced immunological response was detected in 9/10 patients with increased lymphoid infiltrates, clonal T cell expansion and diverse T cell phenotypes in post-treatment samples. In tumour-draining (sentinel) lymph nodes, significant clonal overlap with treatment-induced intratumoural T cell expansion was demonstrated.

Conclusions

Neoadjuvant ICB is safe and feasible in MMRd EC. Two cycles of pembrolizumab induced pathologic, radiologic and immunologic responses. Investigation of extended neoadjuvant treatment is warranted and currently being evaluated.

Clinical trial identification

NCT04262089, EudraCT 2018-001816-31.

Editorial acknowledgement

Legal entity responsible for the study

UMCG.

Funding

Dutch Cancer Society (drug supply by MSD without funding).

Disclosure

M. de Bruyn: Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply (pembrolizumab): Merck; Financial Interests, Institutional, Research Grant: Genmab, Mendus, BioNovion, Aduro Biotech, Vicinivax; Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply: BioNTech; Financial Interests, Personal, Stocks/Shares: Sairopa. D.N. Church: Non-Financial Interests, Personal, Speaker, Consultant, Advisor, Consultancy for Merck: Merck; Financial Interests, Institutional, Research Funding: Haliodx. V.H. Koelzer: Financial Interests, Institutional, Research Grant: Indica Labs, Roche, Promedica Foundation. M. Jalving: Financial Interests, Institutional, Advisory Board, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board, Advisory board: Merck. A.K.L. Reyners: Financial Interests, Institutional, Other, Member of the board: Dutch Society of Medical Oncology; Financial Interests, Institutional, Coordinating PI, FIRST study; coordinator for the Netherlands: Tesaro; Financial Interests, Institutional, Local PI, Local PI GCT1015-05 study: Genmab; Financial Interests, Institutional, Local PI, Local PI for the RUBY study: Tesaro; Financial Interests, Institutional, Local PI, Local PI of the R2810 study: Regeneron; Financial Interests, Institutional, Local PI, PI of MK3475-C93 trial: Merck; Non-Financial Interests, Leadership Role, Chairperson of the group that advises the Dutch Society of Medical Oncology whether EMA authorised medication should be common practice in the Netherlands (cieBOM): Dutch Society of Medical Oncology. H.W. Nijman: Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply (pembrolizumab): Merck; Financial Interests, Institutional, Research Grant: Genmab, BioNovion, Aduro Biotech, Vicinivax; Financial Interests, Institutional, Principal Investigator: Mendus; Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply: BioNTech; Financial Interests, Personal, Stocks/Shares: Sairopa, Vicinivax; Financial Interests, Institutional, Advisory Role: Merck; Non-Financial Interests, Personal, Leadership Role, Director Clinical Research: Vicinivax. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.